

CURRICULUM VITAE

DOC. MUDR. MGR. MAREK MRAZ, PHD.

EDUCATION

- 2012 – **Ph.D.** in Oncology; Faculty of Medicine; Masaryk University
- 2009 - **MUDr./M.D.** in General Medicine; Faculty of Medicine; Masaryk University
- 2008 - **Mgr./MSc.** in Molecular Biology; Faculty of Science, Masaryk University
- 2015 – **Assistant Professor of Oncology**, Masaryk University and University Hospital Brno

PROFESSIONAL EXPERIENCES

- **Principal Investigator (since 2014) and Group leader (since 2016)**, Central European Institute of Technology (CEITEC MU) and University Hospital Brno
- **2011-2014 Post-Doctoral (M.D.) Research Fellow**, University of California-San Diego, San Diego, US Laboratory of CLL Biology (supervisor Prof. T.J. Kipps, MD)
- **2009-2010 Post-Doctoral (M.D.) Research Fellow**, Mayo Clinic, Dept. of Hematology, Rochester, US Laboratory of Lymphoma Biology (supervisor Prof. T. Witzig, MD and Prof. G. Nowakowski, MD) Laboratory of CLL Biology (supervisor Prof. C. Zent, MD)

AWARDS AND ACHIEVEMENTS

- 2016 - J.V. Kostir Award for excellence in science (Czech Society of Biochemistry and Molecular Biology)
- 2016 - Award from the Purkyne Foundation (Prague)
- 2015 - Award of the rector of Masaryk University for excellence in science for young investigators
- 2015 - Award of the Czech Society for Oncology for the most influential scientific publication in 2014
- 2014 - Discovery Award for Innovation in Biomedicine (Novartis)
- 2014- European Hematology Association Research Award
- 2013- SoMoPro Award
- 2012 - Best presentation at the Young Investigators Meeting in CLL (Cologne, Germany)
- 2012-2009 - abstract awards by the org. committee of the 13th EHA, 14th EHA, 51ST ASH, 54TH ASH Meeting
- 2011 - Award of the Ministry of Education of Czech Rep. for outstanding student of PhD programs
- 2011, 2008 - Award „Young Czech Hematologists“ by committee of the Prague Hematology Day
- 2010 - Award of the Faculty of Medicine MU for the most influential scientific publication in 2009
- 2009 - 1st Prize for Young Scientist in Biology and Biochemistry awarded by Sigma - Aldrich

MEMBERSHIP

- American Association for Cancer Research
- European Research Initiative on CLL (ERIC)
- European Hematology Association (EHA)
- European Leukemia Net (ELN)
- Czech Society of Hematology
- Czech Leukemia Study Group for Life (CELL)
- Czech Society of Oncology
- Czech Soc for Biochemistry and Molecular Biol.
- Genetic Society of J.G. Mendel

REVIEWER FOR JOURNALS

- Blood
- Leukemia
- Haematologica
- Leukemia and Lymphoma
- Stem Cells
- Plos One
- *and others*

TEACHING ACTIVITIES

- Faculty of Medicine, Masaryk University, Brno
- Faculty of Sciences, Masaryk University, Brno
- bachelor, diploma and PhD students

OTHER ACTIVITIES:

- Member of Early Career Advisory Committee of the *European Haematology Association*
- Instructor at EMBL microRNA/ncRNA workshop (2011, 2015)

SELECTED PUBLICATIONS

- Gabriela Pavlasova, Marek Borsky, Vaclav Seda, Katerina Cerna, Jitka Osickova, Michael Doubek, Jiri Mayer, Raffaele Calogero, Martin Trbusek, Sarka Pospisilova, Matthew S. Davids, Thomas J. Kipps, Jennifer R. Brown, **Marek Mraz**. Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis. **Blood**. 2016. 1 Aug [epub ahead of print]. **Impact factor: 11,5; corresponding author**
- Musilova K, **Mraz M**. MicroRNAs in B cell lymphomas: How a complex biology gets more complex. **Leukemia**. In press, accepted Dec 2014 [Epub ahead of print] **Impact factor: 9,4; corresponding author**
- **Mraz M**, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ. MicroRNA-150 contributes to the proficiency of B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1 genes. **Blood**. 2014 May 1. [Epub ahead of print] **Impact factor: 9,8**
- Cui B, Chen L, Zhang S, **Mraz M**, Fecteau JF, Yu J, Ghia EM, Zhang L, Bao L, Rassenti LZ, Messer K, Calin GA, Croce CM, Kipps TJ. MicroRNA-155 Influences B-cell Receptor Signaling And Associates With Aggressive Disease In Chronic Lymphocytic Leukemia. **Blood**. 2014. **Impact factor: 9,8**
- Dolezalova D, **Mraz M***, Barta T, Plevova K, Vinarsky V, Holubcova Z, Jaros J, Dvorak P, Pospisilova S, Hampl A. MicroRNAs Regulate p21(Waf1/Cip1) Protein Expression and the DNA Damage Response in Human Embryonic Stem Cells. *Stem Cells*. 2012;30(7):1362-72. **Impact factor: 7,8; shared first author and corresponding author.**
- **Mraz M***, Dolezalova D, Plevova K, Stano Kozubik K, Mayerova V, Cerna K, Musilova K, Tichy B, Pavlova S, Borsky M, Verner J, Doubek M, Brychtova Y, Trbusek M, Hampl A, Mayer J, Pospisilova S. MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. **Blood**. 2012 Mar 1;119(9):2110-3. **Impact factor: 10,6; first and corresponding author.**
- **Mraz M**, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE, Nowakowski GS. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α -4- β -1 (VLA-4) with natalizumab can overcome this resistance. **Br J Haematol**. 2011;155(1):53-64.; **Impact factor: 4,9**
- **Mraz M**, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J, Stano Kozubik K, Smardova J, Brychtova Y, Doubek M, Trbusek M, Mayer J, Pospisilova S. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. **Leukemia**. 2009;23(6):1159-63.; **Impact factor: 8,9**
- Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V, Savvulidi F, Kokavec J, Necas E, Berkova A, Obrtlíkova P, Karban J, **Mraz M**, Pospisilova S, Mayer J, Trnny M, Zavadil J, Stopka T. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. **Blood**. 2011;117(14):3816-25.; **Impact factor: 10,6**
- Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M, Vranova V, **Mraz M**, Skuhrova Francova H, Doubek M, Brychtova Y, Kuglik P, Pospisilova S, Mayer J. Missense Mutations Located in Structural p53 DNA-binding Motifs Are Associated with Extremely Poor Survival in Chronic Lymphocytic Leukemia. **Journal of Clinical Oncology**. 2011;29(19):2703-8.; **Impact factor: 18,9**

PATENT: The use of miR-34a and miR-150 for prognostication and prediction of response in B cell malignancies, Patent number: CZ 306080 (date 7/2016)